Business Wire

Debiopharm Highlights Clinical Momentum Across DDR Portfolio at ESMO 2026, Advancing WEE1-Based Therapies in Ovarian and Uterine Cancers and Glioblastoma

20.10.2026 14:00:00 CEST | Business Wire | Press Release

Share

Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standard of care to cure cancer and infectious diseases, today announced their upcoming Phase 1/Phase 2 clinical updates at the European Society for Medical Oncology (ESMO) Congress (Madrid, Spain, 23-27 October). During the event, Debiopharm will highlight clinical updates on its pipeline targeting the DNA Damage Response (DDR), featuring single-agent data on zedoresertib (Debio 0123) as well as rational combination strategies, with both temozolomide in glioblastoma and with lunresertib (Debio2513) in solid tumors.

Debiopharm’s planned activities at ESMO 2026 include:

  • Rapid Oral Presentation (Debio 0123-GBM-105 / NCT05765812): Presenting dose escalation data evaluating zedoresertib in combination with temozolomide in patients with recurrent or progressive glioblastoma.
  • Poster Presentation (Debio 0123-102 / NCT05109975): Presenting Phase 1 expansion data evaluating single-agent zedoresertib in advanced solid tumors, including uterine serous carcinoma and Cyclin E1-overexpressing high-grade ovarian cancer.
  • Meet-the-Expert Event (MYTHIC Study): An invitation-only session alongside the congress during which leading international oncology experts will discuss emerging data from the MYTHIC clinical trial (Debio 0123-106 / NCT04855656), dual WEE1/PKMYT1 checkpoint inhibition, and precision biomarker selection.

“The data to be presented at ESMO 2026 reinforce our belief that zedoresertib has the potential to become a breakthrough therapy in oncology in combination with key agents across multiple tumor types,” expressed Esteban Rodrigo Imedio, Executive Medical Director, Oncology at Debiopharm. “From establishing single-agent disease control in solid tumors and confirming blood-brain barrier penetrance in glioblastoma to advancing dual WEE1/PKMYT1 targeting in the MYTHIC trial, we are committed to unlocking the benefits of synthetic lethality for patients battling hard-to-treat cancers.”

Clinical Progression: Monotherapy, Glioblastoma, and Combination Strategies

Zedoresertib (Debio 0123) is a potent, oral, brain-penetrant, and highly selective WEE1 kinase inhibitor. In the monotherapy expansion study (Debio 0123-102), continuous daily administration of zedoresertib at the recommended Phase 2 dose demonstrated a manageable safety profile alongside evidence of target engagement and signals of activity in heavily pretreated solid tumors, particularly uterine serous carcinoma and ovarian cancer. In parallel, the Debio 0123-GBM-105 clinical trial in recurrent glioblastoma confirmed early signals of antitumor activity, central nervous system penetration and a manageable safety profile in combination with temozolomide, supporting ongoing evaluation in randomized cohorts.

Supported by this favorable tolerability profile and single-agent foundation, Debiopharm has expanded zedoresertib’s clinical evaluation into rational combination regimens. The ongoing MYTHIC trial evaluates zedoresertib in combination with lunresertib, a first-in-class, selective oral PKMYT1 inhibitor, in patients with advanced solid tumors, particularly ovarian cancer.

Therapeutic Rationale: Exploiting Synthetic Lethality in DDR

The scientific rationale underlying Debiopharm’s DDR pipeline focuses on targeted cell-cycle checkpoint disruption. Combining WEE1 and PKMYT1 inhibition creates a dual-checkpoint blockade within the G2/M transition, preventing cancer cells from repairing DNA damage and inducing mitotic catastrophe. Early clinical data from the MYTHIC study indicate promising signs of synthetic lethality and tumor regression in biomarker-selected populations, notably patients harboring CCNE1 amplification as well as FBXW7 or PPP2R1A alterations. Clinical development continues to refine combination dosing and biomarker selection in the MYTHIC trial for solid tumors, while advancing randomized expansion cohorts to evaluate zedoresertib with temozolomide in glioblastoma.

ESMO 2026 Presentation Details

Session Type

Date & Time

Presentation Title / Location

Presenter / Host

Rapid Oral
(CNS Tumours)

Friday, Oct 23 14:07 – 14:12

699RO: Dose Escalation of Debio 0123 Plus Temozolomide in Recurrent/Progressive Glioblastoma

Dr. Maria Vieito
(Vall d'Hebron)

Poster Presentation
(Gynecological Cancers)

Monday, Oct 26
12:00 – 12:45

1273P (Abstract #3519): Expansion data disclosure of the Phase 1 trial of WEE1 inhibitor zedoresertib

Dr. Maria M. Rubinstein
(MSKCC)

Meet-the-Expert
(Closed Session)

Saturday, Oct 24
16:30 – 18:00

Beyond Biomarkers: Advancing DDR-Targeted Therapy in Ovarian Cancer and Solid Tumors

Debiopharm
(Invitation Only)

ABOUT DNA DAMAGE REPAIR (DDR)

When cells have damaged DNA, they must undergo a repair process known as DDR to survive. Cancer cells rely heavily on DDR as they divide and grow uncontrollably. Inhibition of DDR, particularly in combination with other anticancer agents, prevents cancer cells from repairing their DNA, ultimately activating a programmed cell death process. DDR inhibitors such as zedoresertib (Debio 0123), Debiopharm’s WEE1 inhibitor, are currently being investigated in clinical and preclinical studies.

ABOUT PKMYT1 INHIBITION

Lunresertib (Debio2513) is a first-in-class, oral PKMYT1 inhibitor designed to exploit specific genetic vulnerabilities in solid tumors, such as CCNE1 amplification. PKMYT1 acts as a key regulator at the G2/M checkpoint, and its inhibition reduces CDK1 activity, thereby preventing cancer cells from properly repairing DNA damage and forcing them into programmed cell death. As the most advanced PKMYT1 inhibitor in clinical development, lunresertib has shown encouraging proof-of-concept results both as monotherapy and in combination therapies within the ongoing MYTHIC trial.

DEBIOPHARM’S COMMITMENT TO CANCER PATIENTS

Debiopharm develops innovative therapies that target high unmet medical needs in oncology and infectious diseases. Bridging the gap between disruptive discovery products and real-world patient reach, we identify high potential assets and technologies for in-licensing, clinically demonstrate their safety and efficacy, and then select pharmaceutical commercialization partners to maximize patient access globally.

Learn more about:

Visit us at https://www.debiopharm.com/our-expertise/ddr/

Follow us: https://www.linkedin.com/company/debiopharminternational/

View source version on businesswire.com: https://www.businesswire.com/news/home/20261020575136/en/

Contacts

Debiopharm Contact
Dawn Bonine
Head of Communications
Dawn.bonine@debiopharm.com
Tel: +41 (0)21 321 01 11

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Canada to Join the NATO Innovation Fund to Advance the Local Defence, Security and Resilience Ecosystem21.11.2026 17:00:00 CET | Press Release

Canada announced today it is joining the NATO Innovation Fund, becoming the 25th Allied nation to commit to backing deep tech innovation to address the needs of NATO nations. The Government of Canada is committing EUR 64,590,000 (approximately CAD $100 million) to the firm, with the Business Development Bank of Canada (BDC) holding and managing Canada’s investment in the Fund. This brings total commitments to the NATO Innovation Fund to more than EUR 1.1 billion. Canadian membership will give domestic innovators access to patient capital, opportunities to accelerate the adoption of their technology by governments and businesses across the Alliance, a large network of co-investors, and lessons learned from the NIF’s work to date across 24 participating nations. “Canada has the talent, the innovation, and the ambition to be a global leader in defence and security. The NATO Innovation Fund is helping turn that potential into real capabilities by connecting Canadian innovators with the inv

Persona Earns CEN/TS 18099 High Certification for Injection Attack Detection21.11.2026 15:30:00 CET | Press Release

Persona, the leading global identity platform, today announced that its Android SDK has earned CEN/TS 18099 High certification for injection attack detection (IAD). High certification is the top level of the European standard. The evaluation was run by CLR CERT, the certification body of Cabinet Louis Reynaud (CLR) Labs. CLR Labs is accredited under ISO/IEC 17025, the international standard for testing laboratories, and it edits CEN/TS 18099. This certificated injection attack detection is available to all Persona customers and can be activated by working with Persona's team. Injection attacks skip the camera entirely. Instead of holding a photo or mask up to a lens, fraudsters use virtual cameras, emulators and tampered devices to feed stolen, manipulated, or AI-generated media straight into the verification flow. To the system, the result looks like a real live capture, and traditional liveness checks aren't built to catch it. "Our customers are facing more sophisticated deepfakes, f

Picsart Opens the AI Behind Its Platform to Developers & Businesses20.11.2026 20:54:00 CET | Press Release

Picsart, the AI media production and distribution platform backed by Sequoia Capital and SoftBank Vision Fund 2, today launched Picsart Platform - a multimodal creative AI hub that gives developers the technology behind the platform used by more than 100 million people each month. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261120520968/en/ Picsart Opens the AI Behind Its Platform to Developers & Businesses. They can now build their own video, audio, image features using 250+ models from 30+ providers, alongside Picsart's own editing models, through one API, CLI or MCP server. As new video and image models launch every few weeks, managing separate APIs, API keys, and billing systems creates a fragmented ecosystem. By offering unified access to creative tools, Picsart Platform eliminates fragmentation for all creators, spanning independent developers and corporate marketing teams and studios, by providing access to over 25

NetJets Becomes Official Private Aviation Provider of the Hahnenkamm Races in Kitzbühel20.11.2026 18:45:00 CET | Press Release

NetJets, the global leader in private aviation, is delighted to announce its newest partnership with the Hahnenkamm Races in Kitzbühel, Austria, becoming the event's Official Private Aviation Provider. The Hahnenkamm Races are among the most prestigious and celebrated events in world alpine skiing. They attract athletes, business leaders, international guests and winter sports enthusiasts from around the world. Through this partnership, NetJets and the Hahnenkamm Races are aligning two brands renowned for excellence, precision and world-class experiences. The partnership is an exciting addition to NetJets' growing portfolio of premium lifestyle and sporting partnerships, offering Owners unique opportunities to access one of Europe's most iconic winter sporting events. Alongside premium hospitality and unforgettable behind-the-scenes experiences, the collaboration will help create extraordinary moments for Owners, both in the air and on the ground in Kitzbühel. “Kitzbühel is synonymous

Frontgrade Technologies Help Power Critical Computing and Electronics Aboard NASA’s Roman Space Telescope20.11.2026 18:40:00 CET | Press Release

Frontgrade today announced that technologies from across its space electronics portfolio are supporting multiple mission-critical systems aboard NASA’s Nancy Grace Roman Space Telescope, which successfully launched on August 30, 2026. Roman is NASA’s flagship astrophysics observatory designed to investigate dark energy, discover exoplanets and explore the evolution of the universe. Its onboard electronics include radiation-hardened processors and microelectronics, providing critical processing, communications, power-management and control functions across the spacecraft. At the centre of Roman’s computing architecture are Frontgrade Gaisler’s GR740 and GR712RC processors. The GR740 radiation-hardened quad-core LEON4FT processor serves as the computing engine for the Wildcat Processor Card, used in the spacecraft’s primary and redundant Command and Data Handling systems as well as the Instrument Command and Data Handling systems for both the Wide Field Instrument and Coronagraph Instrum

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye